Michael C. O’Donovan

The paper updates the Psychiatric Genomics Consortium's progress and outlines future goals for translating genetic findings into clinical and therapeutic applications.

The paper investigates the relationship between polygenic risk scores for schizophrenia and psychotic features in bipolar disorder, finding a gradient of genetic liability based on the level of mood-incongruent symptoms.

The paper confirms a polygenic effect on negative symptoms in schizophrenia using GWAS, identifies novel loci, and highlights the need for larger samples.

This study investigates whether polygenic risk scores (PRS) can predict antidepressant response in MDD, finding no significant predictive effect.